ClinicalTrials.gg
Not yet recruitingNCT07704281DépisTrecUpdated Jul 15, 2026

Follow-up of the Cohort of Newborns Screened at Birth Using TREC Analysis

An observational study in Severe Combined Immunodeficiencies (SCID), sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Nantes University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
450
Ages
Up to 5 Years
Sex
All
01

Study summary

Since September 2025, neonatal screening for severe combined immunodeficiency (SCID) has been generalized in France. These genetic disorders, which are asymptomatic at birth, cause severe immunodeficiency, exposing infants to serious infections (viral, bacterial, or fungal) as early as the first year of life. Without early treatment and management, infectious complications can be life-threatening.

Studies show that this screening improves survival and quality of life and reduces treatment costs by enabling intervention before complications arise.

In France, the Ministry of Health referred this matter to the Haute Autorité de Santé (HAS), which issued a favorable opinion in January 2022 via a ministerial decree (published on April 16, 2025) regarding the combined screening for DICS and spinal muscular atrophy. These authorizations follow the DEPISTREC study (2015-2017), which demonstrated the effectiveness of this screening: 190,517 children were screened, resulting in a reduction in DICS-related deaths.

The primary objective of the study will be to describe the underlying causes of T-cell lymphopenia identified in newborns through neonatal screening by quantifying TRECs on Guthrie cards. (SCID; variant SCID; syndromic T-cell deficiency; secondary T-cell deficiency; attenuated SCID; Omenn syndrome; immunosuppressive treatment in the mother; not found; isolated prematurity).

02

Conditions studied

  • Severe Combined Immunodeficiencies (SCID)

Keywords

  • Severe combined immunodeficiencies (SCID)
  • neonatal screening
  • T-cell lymphopenia
  • Guthrie test
03

In context

Severe Combined Immunodeficiency

59 studies on the registry are indexed under Severe Combined Immunodeficiency; 14 are open to participants now.

This study's planned enrollment of 450 is above the median of 100 across 19 observational studies indexed under Severe Combined Immunodeficiency.

Browse Severe Combined Immunodeficiency studies →

Lead sponsor

Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target population consists of all children screened for SCID in France, that is, all children born in metropolitan France and the overseas territories whose parents consent to neonatal screening of their child using the Guthrie test.

Within this population, our cohort will include all children with a positive Guthrie card screening result confirmed by lymphocyte immunophenotyping performed during the first visit with a pediatric specialist. This will include the first baby screened on or after September 1, 2025 (the start date of neonatal screening for DICS in France) and will cover a 5-year period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with a positive Guthrie test result, confirmed by lymphocyte immunophenotyping performed during their first visit with a pediatric specialist.

Exclusion criteria

Exclusion Criteria:

  • Children whose parents objected to the collection of data after receiving the informational letter
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • SCID Children

    Our cohort will include all children with a positive Guthrie test result, confirmed by lymphocyte immunophenotyping performed during their first visit with a pediatric specialist. This will include the first baby screened on or after September 1, 2025 (the start date of neonatal screening for DICS in France) and will cover a 5-year period.

    Other: Data collection

Interventions

  • OtherData collection

    The categories of data processed in the study database will be: * Clinical data * Laboratory data * Data related to newborn screening * Genetic data (only the results of genetic testing) * Care-related data (referral center, dates of tests, etc.)

06

What researchers measure

Primary outcomes

  1. Etiology of T-cell lymphopenia identified through newborn screening using TREC quantification on Guthrie cards

    Time frame: Enrollment

Secondary outcomes

  1. Prevalence of SCID and severe T-cell lymphopenia in the screened population

    Time frame: Enrollment

  2. Description of the clinical management of newborns diagnosed with T-cell lymphopenia, whether SCID or non-SCID

    Time frame: Enrollment

  3. Describe the time frame for reporting test results

    Time frame: Enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2035, 105 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Aug 31, 2035
CompletionEst.
Aug 31, 2035
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704281
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 31, 2035 (estimated)
Completion
Aug 31, 2035 (estimated)
Last update
Jul 15, 2026

Study contacts

Caroline THOMAS
Contact
marie.rimbert@chu-nantes.fr
Marie RIMBERT
Contact
marie.rimbert@chu-nantes.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion